邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

新型冠状病毒肺炎的药物治疗：时机决定预后

曹玮,  李太生

downloadPDF
文章导航 > 协和医学杂志  > 2021 >  12(1): 5-8
曹玮, 李太生. 新型冠状病毒肺炎的药物治疗：时机决定预后[J]. 协和医学杂志, 2021, 12(1): 5-8. doi: 10.3969/j.issn.1674-9081.2021.01.002
引用本文: 曹玮, 李太生. 新型冠状病毒肺炎的药物治疗：时机决定预后[J]. 协和医学杂志, 2021, 12(1): 5-8. doi: 10.3969/j.issn.1674-9081.2021.01.002
shu
CAO Wei, LI Tai-sheng. Treatment of Coronavirus Disease 2019: Timing Determines Prognosis[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 5-8. doi: 10.3969/j.issn.1674-9081.2021.01.002
Citation: CAO Wei, LI Tai-sheng. Treatment of Coronavirus Disease 2019: Timing Determines Prognosis[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 5-8. doi: 10.3969/j.issn.1674-9081.2021.01.002
shu

新型冠状病毒肺炎的药物治疗：时机决定预后

doi: 10.3969/j.issn.1674-9081.2021.01.002

  • 中国医学科学院 北京协和医学院 北京协和医院感染内科，北京 100730

详细信息
    通讯作者:

    LI Tai-sheng Tel: 86-10-69155086, E-mail: litsh@263.net

  • 中图分类号: R51;R18

Treatment of Coronavirus Disease 2019: Timing Determines Prognosis

  • Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

    摘要
  • 摘要: 新型冠状病毒肺炎全球疫情仍在不断蔓延。对这一新发疾病的应对离不开对其临床特点及病理生理机制的研究。尽管目前临床治疗选择仍十分有限，但现有经验已经表明，需根据患者所处的病程阶段和自身免疫特点选择相应的临床治疗策略。本文回顾新型冠状病毒的临床特点及不同类型药物的现有证据，结合一线抗疫经验，总结当前新型冠状病毒肺炎的临床关键节点和相应治疗策略。
    Abstract: The global epidemic of coronavirus disease 2019 (COVID-19) is still growing. The response to this emerging disease should be considered with the context of its clinical characteristics and pathophysiological mechanisms. Although available therapeutic options are still very limited, current experience has suggested that the choice of clinical strategies should be based upon the disease stage and immune functions of the patients. The present article reviews the clinical characteristics of COVID-19 and current evidence of various treatment approaches. Combined with first-line experience, we summarize the current clinical strategies for COVID-19 management based on disease progress and staging.
    作者贡献：曹玮负责资料收集、论文撰写；李太生负责论文审校。
    利益冲突  无
    • HTML全文
    • 参考文献(17)
  • [1] Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019[J].Nature, 2020, 581:465-469. doi:  10.1038/s41586-020-2196-x
    [2] He X, Lau EHY, Wu P, et al.Temporal dynamics in viral shedding and transmissibility of COVID-19[J].Nat Med, 2020, 26: 672-675. doi:  10.1038/s41591-020-0869-5
    [3] Tang N, Li D, Wang X, et al.Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia[J].J Thromb Haemost, 2020, 18: 844-847. doi:  10.1111/jth.14768
    [4] 张炎, 曹玮, 肖盟, 等.合并肢端缺血表现的危重型新型冠状病毒肺炎7例临床分析[J].中华血液学杂志, 2020, 41: 302-307.

    Zhang Y, Cao W, Xiao M, et al.Clinical and coagulation characteristics in 7 patients with critical COVID-2019 pneumonia and acro-ischemia[J]Zhonghua Xue Ye Xue Za Zhi, 2020, 41: 302-307.
    [5] Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19[J].Am J Hematol, 2020, 95:834-847. doi:  10.1002/ajh.25829
    [6] Cao B, Wang Y, Wen D, et al.A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19[J]. N Engl J Med, 2020, 382:1787-1799. doi:  10.1056/NEJMoa2001282
    [7] Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial[J].BMJ, 2020, 369:m1849. http://www.bmj.com/content/369/bmj.m1849
    [8] Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19[J]. N Engl J Med, 2020:NEJMoa2019014.doi:  10.1056/NEJMoa2019014.
    [9] Boulware DR, Pullen MF, Bangdiwala AS et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19[J].N Engl J Med, 2020, 383:517-525. doi:  10.1056/NEJMoa2016638
    [10] Wang Y, Zhang D, Du G, et al.Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial[J]. Lancet, 2020, 395:1569-1578. doi:  10.1016/S0140-6736(20)31022-9
    [11] Beigel JH, Tomashek KM, Dodd LE.Remdesivir for the Treatment of Covid-19- Preliminary Report[J].N Engl J Med, 2020, 383:994.
    [12] 国家卫生健康委员会.新型冠状病毒肺炎重型、危重型病例诊疗方案(试行第二版)[EB/OL]. http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202004/W020200402473702118623.pdf.
    [13] 北京协和医院新型冠状病毒感染的肺炎诊疗专家组.北京协和医院关于"新型冠状病毒感染的肺炎"诊疗建议方案(V2.0)[J].协和医学杂志, 2020, 11:672-675. doi:  10.3969/j.issn.1674-9081.20200022

    Working Group of 2019 Novel Coronavirus Infection, Peking Union Medical College Hospital. Diagnosis and Clinical Management of 2019 Novel Coronavirus(2019-nCoV) Infection:An Operational Recommendation of Peking Union Medical College Hospital(V2.0)[J].Xie He Yi Xue Za Zhi, 2020, 11:672-675. doi:  10.3969/j.issn.1674-9081.20200022
    [14] Recovery Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19- Preliminary Report[J].N Engl J Med, 2020:NEJMoa2021436. doi:  10.1056/NEJMoa2021436.
    [15] Cao W, Liu X, Bai T, et al.High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019[J].Open Forum Infect Dis, 2020, 7:ofaa102. doi:  10.1093/ofid/ofaa102
    [16] 姚小红, 李廷源, 何志承, 等.新型冠状病毒肺炎(COVID-19)3例遗体多部位穿刺组织病理学研究[J].中华病理学杂志, 2020, 49:411-417.

    Yao XH, Li TY, He ZC, et al.A pathological report of three COVID-19 cases by minimally invasive autopsies[J].Zhonghua Bing Li Xue Za Zhi, 2020, 49:411-417.
    [17] Lin L, Lu L, Cao W, et al.Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia[J].Emerg Microbes Infect, 2020, 9:727-732. doi:  10.1080/22221751.2020.1746199
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  647
  • HTML全文浏览量:  256
  • PDF下载量:  225
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-09-21
  • 录用日期:  2020-10-27
  • 网络出版日期:  2020-12-01
  • 刊出日期:  2021-01-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！